The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer

Current Opinion in Urology

Volumn 23, Issue 3, 2013, Pages 194-200

  Ischia, Joseph ^a   Saad, Fred ^b   Gleave, Martin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

castration resistant prostate cancer; heat shock proteins; mechanisms of treatment resistance

Indexed keywords

2' METHOXYETHYL PHOSPHOROTHIOATE; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ABIRATERONE; ALVESPIMYCIN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AT 13387; BERBERINE; CABAZITAXEL; CLUSTERIN; CUSTIRSEN; DOCETAXEL; GANETESPIB; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK PROTEIN INHIBITOR; MJC 13; NVP HSP 990; OGX 427; PANOBINOSTAT; PF 04929113; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN INHIBITOR; RETASPIMYCIN; ROMIDEPSIN; SNX 2112; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL DEATH; CELL PROTECTION; CELL VIABILITY; CIRCULATING TUMOR CELL; CYTOTOXICITY; GENE SILENCING; HEAT SHOCK RESPONSE; HUMAN; KETOACIDOSIS; LIVER FAILURE; LYMPH NODE METASTASIS; MALE; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FOLDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84876420606     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835e9f1a     Document Type: Review

References (38)

1. Calderwood SK, Ciocca DR. Heat shock proteins: stress proteins with Januslike properties in cancer. Int J Hyperthermia 2008; 24:31-39. (Pubitemid 351167617)
2. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006; 31:164- 172. (Pubitemid 43361923)
3. Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol 2012; 44:1646-1656.
4. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64:6595-6602. (Pubitemid 39297919)
5. Zoubeidi A, Zardan A, Beraldi E, et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007; 67:10455-10465. (Pubitemid 350070821)
6. Stope MB, Schubert T, Staar D, et al. Effect of the heat shock protein HSP27 on androgen receptor expression and function in prostate cancer cells. World J Urol 2012; 30:327-331. This article highlights the direct effect of Hsp27 overexpression/silencing on androgen receptor expression in androgen dependent and independent prostate cancer cells.
7. Zoubeidi A, Zardan A, Wiedmann RM, et al. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res 2010; 70:2307-2317.
8. Hayashi N, Peacock JW, Beraldi E, et al. Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death Differ 2012; 19:990-1002. This article identifies a dual coordinated role of Hsp27 in cell proliferation and Fas-induced apoptosis via Akt and PEA-15 (15-kDa phospho-enriched protein in astrocytes), and indicates that improved clinical responses to Hsp27-targeted therapy may be achieved by stratifying patient populations based on tumor PTEN expression.
9. Baylot V,Katsogiannou M,Andrieu C, et al.TargetingTCTPas anewtherapeutic strategyincastration-resistantprostatecancer.MolTher2012;20:2244-2256. This article identifies a new Hsp27-mediated cytoprotection mechanism in CRPC, and provides preclinical proof-of-principle that combining ASO-mediated TCTP (translationally controlled tumor protein) knockdown combined with castration and/or docetaxel therapy could serve as a novel strategy to treat CRPC.
10. Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005; 65:11083-11093. (Pubitemid 41713379)
11. Andrieu C, Taieb D, Baylot V, et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 2010; 29:1883-1896.
12. Choi DH, Ha JS, Lee WH, et al. Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett 2007; 581:1649-1656. (Pubitemid 46528931)
13. Chi KN, Yu EY, Ellard S, et al. OGX-427 in castration resistant prostate cancer patients. 37th ESMO Congress; 28 September to 2 October 2012; Vienna, Austria: Ann Oncol; 2012. p. ix297.
14. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005; 23:38-46. (Pubitemid 40430679)
15. Yu T, Liu X, Bolcato-Bellemin AL, et al. An amphiphilic dendrimer for effective delivery of small interfering RNA and gene silencing in vitro and in vivo. Angew Chem Int Ed Engl 2012; 51:8478-8484. This article and the next report a novel nonviral vector (a dendrimer) for delivering siRNA to produce potent gene silencing and anticancer activity in vitro and in vivo in a prostate cancer model. Currently, small heat shock proteins are not amenable to small molecule inhibition and therefore, antisense oligonucleotides currently provide the only mechanism for inhibiting their expression. This new technology is a promising step forward in delivering the potent silencing effects of siRNA in vivo.
16. Liu X, Liu C, Laurini E, et al. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolaminecore PAMAM dendrimer. Mol Pharm 2012; 9:470-481. Nonviral delivery system for siRNA in vivo that silences the actions of Hsp27 in the treatment of CRPC.
17. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5:761-772. (Pubitemid 41400776)
18. Catelli MG, Binart N, Jung-Testas I, et al. The common 90-kd protein component of nontransformed '8S' steroid receptors is a heat-shock protein. EMBO J 1985; 4:3131-3135.
19. Ai J, Wang Y, Dar JA, et al. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castrationresistant prostate cancer. Mol Endocrinol 2009; 23:1963-1972.
20. Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 2012; 287:19736-19749.
21. Li J, Cao B, Liu X, et al. Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther 2011; 10:1346-1356. This article reports that berberine, a novel Hsp90 inhibitor, disrupts the binding of Hsp90 to androgen receptor. Significantly, androgen receptor splice variants, which are thought to be an important mediator of CRPC, were more susceptible to berberine-induced degradation than the full-length androgen receptor.
22. Heath EI, Hillman DW, Vaishampayan U, et al. A phase II trial of 17-allylamino- 17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008; 14:7940-7946.
23. Pacey S, Wilson RH, Walton M, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011; 17:1561-1570.
24. Oh WK, Galsky MD, Stadler WM, et al. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 2011; 78:626-630.
25. Lamoureux F, Thomas C, Yin MJ, et al. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 2011; 17:2301-2313. PF-04928473 is an Hsp90 inhibitor which appears to be less toxic than 17-AAG derivatives. PF-04928473 induces degradation of androgen receptor and other client proteins important in CRPC, such as Her2, Akt, and ERK. Although PF-04929113 inhibited CRPC tumor growth in vivo, it did not reduce serum prostate-specific antigen (PSA) levels in vivo suggesting that serum PSA may not prove useful as pharmacodynamic tool for this drug which is usually an important endpoint in human phase I/II studies.
26. Centenera MM, Gillis JL, Hanson AR, et al. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 2012; 18:3562-3570.
27. Molife LR, Attard G, Fong PC, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castrationresistant prostate cancer (CRPC). Ann Oncol 2010; 21:109-113.
28. Rathkopf D, Wong BY, Ross RW, et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010; 66:181-189.
29. De Leon JT, Iwai A, Feau C, et al. Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells. Proc Natl Acad Sci U S A 2011; 108:11878-11883. Researchers are targeting various cofactors in the androgen receptor-Hsp90 complex, such as the 52 kDa FK506 binding protein (FKBP52). MJC13 is a small molecule that inhibits androgen receptor function by preventing hormone-dependent dissociation of the Hsp90-FKBP52-androgen receptor complex, and effectively blocks androgen receptor-dependent gene expression and androgenstimulated prostate cancer cell proliferation.
30. Eskew JD, Sadikot T, Morales P, et al. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer 2011; 11:468. Nearly all Hsp90 inhibitors target the N-terminal and are associated with significant toxicity and resistance resulting from induction of the heat shock response (HSR). The authors developed a C-terminal Hsp90 inhibitor, KU174, which demonstrates anticancer activity in prostate cancer cells, but importantly, did not elicit a HSR.
31. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000; 6:1655-1663. (Pubitemid 30305057)
32. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60:170-176. (Pubitemid 30058748)
33. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosteronerepressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000; 60:2547-2554. (Pubitemid 30262451)
34. Shiota M, Zoubeidi A, Kumano M, et al. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Mol Cancer Res 2011; 9:1755-1766.
35. Lamoureux F, Thomas C, Yin MJ, et al. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res 2011; 71:5838-5849. Hsp90 inhibitors trigger a heat shock response, including increased expression of CLU, which attenuates drug effectiveness. Treatment-induced increases in CLU were blocked by OGX-011, which synergistically enhanced the activity of Hsp90 inhibition on CRPC cell growth and apoptosis both in vitro and in vivo. This highlights the synergistic role of inhibiting multiple Hsps in modern prostate cancer therapies.
36. Shiota M, Zardan A, Takeuchi A, et al. Clusterin mediates TGF-beta-induced epithelial-mesenchymal transition and metastasis via twist1 in prostate cancer cells. Cancer Res 2012; 72:5261-5272. This article identifies that clusterin upregulation (via YB-1 transactivation) in response to stress is a critical mediator of paclitaxel resistance in prostate cancer.
37. Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 28:4247-4254.
38. Saad F, Hotte S, North S, et al. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 2011; 17:5765-5773. This article reports that custirsen (OGX-011) along with either docetaxel or mitoxantrone was feasible in patients with progressive metastatic CRPC following first-line docetaxel therapy with correlations between serum CLU and survival. Significantly, pain relief was higher than expected, prompting a phase III trial evaluating the pain palliation benefit of custirsen with taxane therapy which is has completed accrual.